Company intelligence / Profile preview

Emperra

Potsdam, Brandenburg, Germanyemperra.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Emperra’s ESYSTA system is a CE-certified, integrated telemedicine solution combining smart insulin pens, blood glucose meters, apps, and an online portal. Clinical trials have demonstrated its impact on improving HbA1c in patients with type 1 and type 2 diabetes. The company has completed a Phase 4 study evaluating real-world effectiveness of the ESYSTA system. A scientifically controlled study for permanent reimbursement as a digital health application (DiGA) was recently completed in Germany.

Therapeutic areas: Endocrinology
Modalities: DeviceSoftware
Industry: Digital Health Medical Devices

Partnerships

Exploring strategic partnerships for international expansion and potential exitPast collaborations with market-leading companies to develop GSM-compatible blood glucose meters

Beyond the preview

Go deeper on Emperra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emperra.

Explore the full profile